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an AMPK-dependent decrease in mTORC1 activity and in-
creases hypothalamic AgRP mRNA levels, the latter effect 
being prevented by insulin in an mTORC1-dependent man-
ner. In conclusion, mTORC1 acts as an integration node in 
hypothalamic neurons for hormone-derived PI3K and AMPK 
signalling and mediates at least part of the assimilated out-
put of anorexigenic and orexigenic hormone actions in the 
hypothalamus. 
 
Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Dysregulation of appetite or loss of caloric sensing can 
have a major impact on health and quality of life. When 
appetite suppression is blunted, obesity and associated 
comorbidities ensue  [1] . Alternatively in conditions such 
as cancer, sepsis and ageing, appetite is suppressed, which 
exacerbates the associated cachexia/sarcopenia  [2] . Con-
sidering the worldwide projections for obesity and the 
ageing population, it is vital to understand the molecular 
mechanisms regulating appetite and energy metabolism 
as this information may yield suitable pharmacological 
targets for the treatment of obesity and wasting. Energy 
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 Abstract 
 Activation of mammalian target of rapamycin 1 (mTORC1) by 
nutrients, insulin and leptin leads to appetite suppression 
(anorexia). Contrastingly, increased AMP-activated protein 
kinase (AMPK) activity by ghrelin promotes appetite (orexia). 
However, the interplay between these mechanisms remains 
poorly defined. The relationship between the anorexigenic 
hormones, insulin and leptin, and the orexigenic hormone, 
ghrelin, on mTORC1 signalling was examined using S6 kinase 
phosphorylation as a marker for changes in mTORC1 activity 
in mouse hypothalamic GT1-7 cells. Additionally, the contri-
bution of AMPK and mTORC1 signalling in relation to insulin-, 
leptin- and ghrelin-driven alterations to mouse hypothalam-
ic agouti-related protein (AgRP) mRNA levels was examined. 
Insulin and leptin increase mTORC1 activity in a phos-
phoinositide-3-kinase (PI3K)- and protein kinase B (PKB)-de-
pendent manner, compared to vehicle controls, whereas in-
creasing AMPK activity inhibits mTORC1 activity and blocks 
the actions of the anorexigenic hormones. Ghrelin mediates 
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homeostasis is maintained, in part, through regulation of 
body fat stores via feedback signals arising from fat de-
pots that are sensed by neurons in the hypothalamus. For 
example, leptin and insulin, made and released from ad-
ipocytes and pancreatic beta cells, respectively, circulate 
in proportion to body fat levels and access the basome-
dial hypothalamus via specialized uptake systems  [3, 4] . 
In contrast, ghrelin, an orexigenic hormone, is produced 
predominantly in the stomach and readily transported 
into the hypothalamus, although ghrelin is also ex - 
pressed and released by a small population of hypotha-
lamic neurons potentially allowing a local, fine control of 
neuronal function  [5] . These hormones control food in-
take and energy balance by regulating orexigenic and an-
orexigenic peptide levels and release by neurons in the 
arcuate nucleus (ARC) of the hypothalamus  [3, 6] . Insulin 
and leptin suppress expression of orexigenic agouti-relat-
ed peptide (AgRP) and neuropeptide Y (NPY) and pro-
mote anorexigenic pro-opiomelanocortin (POMC)-de-
rived peptide production. Conversely ghrelin, which in-
creases appetite and fat deposition, increases NPY and 
AgRP and reduces POMC neuropeptide expression and 
release, respectively  [5, 7] . 
 The precise mechanisms involved in the regulation of 
hypothalamic peptide expression and release remain to 
be fully determined. Recent studies have indicated a key 
role for the class 1A phosphoinositide-3-kinases (PI3Ks) 
in the signalling cascades linking leptin and insulin with 
modulation of ARC neuron neuropeptide expression and 
electrical activity  [3, 4] . Thus, PI3K is an important inte-
gration node for leptin and insulin action on ARC neu-
rons. However, the role of downstream mediators and the 
contributions of additional signalling pathways that act 
to modify PI3K-driven outputs in ARC neurons are un-
clear. An important signalling component downstream 
from PI3K in the hypothalamus is the mammalian target 
of rapamycin complex 1 (mTORC1), which activates the 
S6 kinases (S6K1 and S6K2). Refeeding-, amino acid- or 
leptin treatment increases ARC mTORC1-S6K activity in 
association with appetite suppression, actions attenuated 
by the specific mTORC1 inhibitor, rapamycin  [8, 9] . Fur-
thermore, mTORC1 activity is predominantly located to 
the ARC and highly colocalized to leptin receptor-ex-
pressing NPY/AgRP and, to a lesser extent, POMC neu-
rons  [8, 9] . These data are consistent with ARC mTORC1-
S6K activity involvement in anorexigenic signalling. In-
deed, recent studies have demonstrated that decreased 
hypothalamic mTORC1-S6K signalling is causally linked 
to diet-induced obesity and leptin resistance  [10–12] . 
However, mice globally deficient in S6K are lean, insulin 
sensitive and resistant to obesity induced by high-fat diets 
 [13] . This may be explained by the observation that hy-
peractive mTORC1 activity in liver and muscle is associ-
ated with insulin resistance and metabolic dysfunction 
 [14, 15] . Taken together, these data indicate that dysregu-
lated mTORC1 activity either centrally or peripherally 
has significant consequences for metabolic status, with 
the final outcome also dependent on the site of modifica-
tion. 
 Ghrelin stimulates food intake by acting as an ago - 
nist on the growth hormone secretagogue receptor 1a 
(GHSR1a) within the hypothalamus  [16, 17] . Central ad-
ministration of ghrelin increases ARC AgRP and NPY 
mRNA levels and induces c-fos and Egr-1 in NPY/AgRP 
ARC neurons, indicative of increased neuronal activity 
 [7, 18, 19] . The appetite-promoting effects of peripheral 
and central ghrelin treatment have largely been attrib-
uted to stimulation of AMP-activated protein kinase 
(AMPK), an enzyme activated during fuel deficiency to 
promote catabolic and inhibit anabolic pathways  [20, 
21] . Indeed, hypothalamic expression of a constitutively 
active form of AMPK or direct pharmacological activa-
tion of hypothalamic AMPK using the AMP analogue, 
AICAR, increases food intake and expression of AgRP 
and NPY mRNA  [20, 22] . Importantly, AMPK activa-
tion inhibits mTORC1 activity in a variety of cell types 
 [23] . However, it is unclear whether ghrelin-mediated 
induction of hypothalamic AgRP/NPY gene expression 
involves AMPK and/or mTORC1 signalling. It is also 
uncertain whether mTORC1 is a downstream signalling 
node in hypothalamic neurons, capable of integrating 
anorexigenic and orexigenic signals through AMPK 
and PI3K pathways to mediate control of orexigenic 
neuropeptides. Therefore, we used the mouse hypotha-
lamic GT1-7 cell line to investigate the interaction be-
tween anorexigenic (leptin and insulin) and orexigenic 
(ghrelin) hormone signalling on mTORC1 activity and 
mouse hypothalamic basomedial tissue sections to de-
termine whether these signalling processes are involved 
in hormone-mediated changes in AgRP mRNA expres-
sion.
 Materials and Methods 
 Cell Culture 
 The mouse-derived hypothalamic GT1-7 cell line was main-
tained in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich, 
Dorset, UK) supplemented with 10% fetal bovine serum (PAA 
Laboratories, Yeovil, UK) as described previously  [24] . 
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 Immunoblotting 
 Confluent GT1-7 cells, in 6-well dishes, were serum starved 
for 3 h prior to hormone: leptin 50 n M (R&D Systems, Abingdon, 
UK), insulin 50 n M (Novo Nordisk, Crawley, UK), or ghrelin 100 
n M (Tocris Bioscience, Bristol, UK) and/or drug: wortmannin 
100 n M (Sigma-Aldrich, Gillingham, UK), LY294002 10   M , 
Akti 10   M , rapamycin 100 n M , compound C 40   M , STO-609 
10   M (all Merck Chemicals Ltd., Nottingham, UK) and A-769662 
50   M (Ascent Scientific, Bristol, UK) treatment for various 
times, as described in the Results section. All drugs were dis-
solved in saline or 0.1% DMSO, unless otherwise stated. Total 
protein lysates from the cells were subjected to SDS-PAGE, elec-
trotransferred to a nitrocellulose membrane. Non-specific pro-
tein binding sites were blocked by a 60-min incubation in 5% 
(w/v) skimmed milk in Tris-buffered saline supplemented with 
0.5% (v/v) Tween 20. The membrane was then incubated over-
night at 4   °   C using 5% milk solution supplemented with the ap-
propriate primary antibody. Following three washes with 5% 
milk solution, the membranes were incubated with 5% milk solu-
tion supplemented with horseradish peroxidase-conjugated anti-
IgG antibody (Fisher Scientific, UK) for 60 min at room temper-
ature. After three further washes with 5% milk solution and two 
washes with Tris-buffered saline, the immunoreactive proteins 
were identified by enhanced chemiluminescence (GE Health-
care, UK). Primary antibodies used were: p-S6K (p85 S6K 
(Thr412) and p70 S6K (Thr389); 1: 1,000), p-AMPK  (Thr172;
1: 1,000), p-ACC (Ser79; 1: 1,000), ACC (1: 1,000) all from New 
England Biolabs, Hitchin, UK; S6K (1: 1,000; Cambridge Biosci-
ence, Cambridge, UK), Actin (1: 5,000; Sigma-Aldrich) and 
AMPK  1 (1: 5,000) and AMPK  2 (1: 10,000), both of which were 
kind gifts from Grahame Hardie (University of Dundee). Protein 
bands on gels were quantified by densitometry using Aida Image 
Data Analyzer software (version 3), where total density was de-
termined with respect to constant area, background was sub-
tracted and average relative band density was calculated. Phos-
phoprotein levels are presented as normalized values in relation 
to control and as a ratio of non-phosphorylated total levels at 
equivalent time points.
 AMPK Activity Assay 
 GT1-7 cells were serum starved for 3 h, prior to stimulation 
with either 100 n M ghrelin or 50   M A-769662 for 30 min. The 
cells were washed twice with PBS and lysed in lysis buffer (50 m M 
Tris-HCl pH 7.5, 150 m M NaCl, 50 m M NaF, 5 m M NaPPi, 1 m M 
EDTA, 1 m M EGTA, 1 m M DTT, 0.1 m M benzamidine, 0.1 n M 
PMSF, 5   g/ml soyabean trypsin inhibitor, 1% (v/v) Triton X-100), 
with insoluble debris removed by centrifugation and the protein 
content determined (BCA assay, Thermo Scientific). AMPK ac-
tivity was determined as previously described  [25] . AMPK activ-
ity was calculated using the difference of the counts between 
AMARA (AMPK substrate: AMARAASAAALARRR) contain-
ing and AMARA-negative samples and calculated as nanomoles 
of ATP incorporated per minute per milligram of sample peptide. 
Data represented are normalized to control and are the average of 
4–6 independent experiments with 3 replicates in each experi-
ment.
 Calcium Imaging 
 GT1-7 cells were serum starved for 3 h prior to calcium imag-
ing using a conventional MetaMorph imaging system (Universal 
Imaging Corporation, Marlow, UK) with a Zeiss Axiovert 200 
inverted epifluorescence microscope equipped with a  ! 40 oil im-
mersion objective. Cells were loaded with fura-2 AM (Sigma-Al-
drich) for 45 min at 37   °   C in dark conditions in incubation me-
dium containing 135 m M NaCl, 5 m M KCl, 1 m M MgCl 2 , 2.5 m M 
glucose, 10 m M leucine, 1 m M CaCl 2 , 10 m M HEPES, pH 7.4). Cells 
were maintained at 35  °  C and selected for measurement by place-
ment of Triton-X100 regions of interest around their somata. The 
fluorescence emission at 510 nm was collected for alternating ex-
citations at 340 and 380 nm and expressed as a ratio of emission 
fluorescence (340/380 nm). The ratiometric images were collected 
at 5- to 30-second intervals. This was increased to 2-second inter-
vals during the first 5 min of drug application. Data from 7 sepa-
rate experiments were derived from the somata of 5–15 cells with-
in a field and are presented as percentage of change in fluorescent 
ratio, which is proportional to the intracellular calcium concen-
tration. 
 Electrophysiology 
 GT1-7 cells were superfused at room temperature (22–25   °   C) 
with normal saline (135 m M NaCl, 5 m M KCl, 1 m M MgCl 2 , 1 m M 
CaCl 2 , 10 m M Hepes, 2.5 m M glucose and 1 m M  L -leucine, pH 7.4). 
Recordings were made using borosilicate glass pipettes (5–10 
M  ) containing 140 m M KCl, 5 m M MgCl 2 , 3.8 m M CaCl 2 , 10 m M 
Hepes and 10 m M EGTA (pH 7.2). Perforated patch recordings 
were achieved by the addition of 25–40   M amphotericin B (Sig-
ma-Aldrich) to the pipette solution. Following a minimum of 10 
min of stable recording, 100 n M ghrelin was applied by bath su-
perfusion.
 Preparation of Mouse Hypothalamic Slices and Measurement 
of AgRP Gene Expression 
 Male or female adult C57BL6/J mice were maintained on a 12-
hour light-dark cycle with free access to water and chow. All ani-
mal care protocols and procedures were performed in accordance 
to the Animal Scientific Procedures Act (1986) and with approval 
of the University of Dundee Animal Ethics Committee. Animals 
were fasted for 1 h prior to experiments. The preparation of hy-
pothalamic slices was as previously described  [24] . In brief, hori-
zontal 400-  m coronal brain slices were prepared using a Vibra-
tome (Intracel, Royston, UK) and hypothalamic ARC wedges 
were cut and incubated in aCSF  8 A-769662 (50   M ), ghrelin (100 
n M ), insulin (50 n M ) or leptin (50 n M )  8 rapamycin (100 n M ) or 
compound C (40   M ), or combinations thereof, for
3 h. Following tissue homogenization and RNA isolation, reverse 
transcription-PCR was performed using Superscript II (Life 
Technologies, Paisley, UK) and random primers. AgRP gene ex-
pression was then assayed by real-time PCR using a premixed 
mouse AgRP primer-probe set purchased from Applied Biosys-
tems (Foster City, Calif., USA).
 Statistics 
 Comparisons between groups were made by the unpaired or 
paired 2-tailed Student’s t test, one-sample t test or analysis of 
variance with repeated measures and Bonferroni post-test anal-
ysis, as appropriate. Values represent mean  8 SEM. p values  ^  
0.05 were considered statistically significant.
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 Results 
 Insulin and Leptin Increase S6K Phosphorylation 
Levels in GT1-7 Cells 
 To explore the mechanisms by which leptin, insulin 
and ghrelin alter mTORC1 signalling, we utilized chang-
es in S6K phosphorylation (p-S6K) levels as a surrogate 
marker for mTORC1 activity in GT1-7 cells. Previous 
studies have shown that leptin and insulin increase activ-
ity through the PI3K signalling pathway in these cells  [24] 
and that regulation of PI3K-dependent signalling is im-
portant for modulation of mTORC1-dependent S6K ac-
tivity  [26] . Immunoblots for pS6K generally exhibit two 
bands; the upper band represents p-85 S6K (Thr412) and 
the lower band p-70 S6K (Thr389). Control experiments 
demonstrated that leptin and insulin do not alter total 
levels of S6K over this time period (data not shown), 
whereas both hormones increase p-S6K levels ( fig. 1 a, b).
 In order to confirm a role for PI3K in leptin- and in-
sulin-induced S6K phosphorylation, GT1-7 cells were 
pre-treated with vehicle or the PI3K inhibitors, wortman-
nin (100 n M ) or LY294002 (10   M ) for 20 min prior to 
leptin or insulin stimulation (in the continued presence 
of inhibitor or vehicle). Basal S6K phosphorylation was 
not significantly affected by wortmannin, whereas 
LY294002 almost completely suppressed basal p-S6K 
( fig. 1 a–f). Both inhibitors were effective blockers of the 
insulin- ( fig. 1 a, c, e) and leptin- ( fig. 1 b, d, f) mediated 
increase in p-S6K. The ability of LY294002 to suppress 
p-S6K more than wortmannin may be due to this concen-
tration of LY294002 directly inhibiting mTORC1 activ-
ity more than 100 n M wortmannin  [27, 28] . Increased 
mTORC1 activity elicited by growth factors is reported to 
be dependent on PI3K signalling through the PKB/Akt 
pathway  [29] . Therefore, to determine whether insulin 
and leptin utilize this pathway, GT1-7 cells were pre-in-
cubated (as above) with the selective PKB inhibitor Akti 
 [30] or the highly selective mTORC1 inhibitor, rapamycin 
 [28] . The PKB inhibitor, Akti (10   M ), prevented the in-
sulin- ( fig. 2 a, c) and leptin-mediated ( fig. 2 b, d) increas-
es in p-S6K, with the inhibitor having no significant 
 effect on basal p-S6K. In contrast, 100 n M rapamycin 
a d
e
f
b
c
 Fig. 1. PI3K signalling mediates increased 
S6K phosphorylation by insulin and leptin 
in GT1-7 cells.  a Representative immuno-
blots for S6K in GT1-7 cells in response to 
50 n M insulin, 10   M LY294002 (Ly) and 
100 n M wortmannin (Wm) alone and to 
insulin in the presence of LY294002 or 
wortmannin. C = Control.  b Representa-
tive immunoblot of p-S6K in response to 
50 n M leptin, 10   M LY294002 and 100 n M 
wortmannin alone and to leptin in the 
presence of LY294002 or wortmannin. C = 
Control.  c ,  d Mean normalized p-S6K un-
der non-stimulated conditions (Cont), in-
sulin (Ins), wortmannin and LY294002, 
and insulin in the presence of wortman-
nin (Ins-Wm) and LY294002 (Ins-Ly)
at time point 30 min.  e ,  f Mean normalized 
p-S6K under non-stimulated conditions 
(Cont), leptin (Lep), wortmannin and 
LY294002, and leptin in the presence of 
wortmannin (Lep-Wm) and LY294002 
(Lep-Ly) at time point 30 min. n = 3–6 for 
each condition. Values are mean  8 SEM. 
 *  p  ! 0.05;  * *  p  ! 0.01;  * * *  p  ! 0.001. 
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abolished basal, insulin- and leptin-induced S6K phos-
phorylation ( fig. 2 e–h). Thus, leptin and insulin increase 
S6K phosphorylation in GT1-7 cells, utilizing a pathway 
that depends upon the activity of the PI3K-PKB-mTORC1 
pathway.
 Modulation of AMPK by A-769662 or Ghrelin Leads 
to an Inhibition of mTORC1 Signalling 
 Raised hypothalamic AMPK activity increases AgRP 
mRNA expression levels concomitant with increased 
food intake  [22] . Importantly, a recent study has demon-
strated that the orexigenic effect of ghrelin is mediated by 
an AMPK-dependent increase in AgRP and NPY mRNA 
expression  [31] . However, the modulation of hypotha-
lamic mTORC1 activity by AMPK and ghrelin has not 
been fully investigated and little is known regarding this 
signalling pathway in relation to orexigenic peptide ex-
pression. Exposure of GT1-7 cells to the direct activator 
of AMPK, A-769662 (50   M ), caused a rapid increase in 
AMPK phosphorylation (p-AMPK) that was sustained 
for at least 60 min, with no effect on total AMPK ( fig. 3 a, 
b). This action of A-769662 correlated with a parallel in-
crease in the phosphorylation of the AMPK downstream 
effector, acetyl-CoA carboxylase (p-ACC), indicating in-
creased activity of AMPK ( fig.  3 a, c). Consistent with
a model where AMPK inhibits mTORC1 signalling, 
A-769662 attenuated basal p-S6K in a time-dependent 
manner ( fig. 3 a, d), which paralleled the A-769662-medi-
ated AMPK phosphorylation, with no effect on total S6K 
protein levels ( fig. 3 a). Insulin and leptin, over this time 
a e
f
g
h
b
c
d
 Fig. 2. Increased p-S6K by insulin and 
leptin is PKB- and  mTORC1-dependent. 
Representative immunoblots for p-S6K 
under control conditions (C), 10   M Akti 
(Akti) and 50 n M insulin ( a ) or 50 n M 
leptin ( b ) in the absence and presence of 
Akti. Mean normalized p-S6K under non-
stimulated conditions (Cont), Akti, and 
insulin in the absence (Ins) and presence 
(Ins-Akti) of Akti ( c ) and leptin ( d ) in the 
absence (Lep) and presence (Lep-Akti) of 
Akti at the 30-min time point. Representa-
tive immunoblots for p-S6K under control 
conditions, 100 n M rapamycin (Ra) and in 
response to 50 n M insulin ( e ) or 50 n M 
leptin ( f ) in the absence and presence of 
rapamycin. Mean normalized p-S6K un-
der non-stimulated conditions (Cont), 
rap amycin (Ra), and  insulin ( g ) in the ab-
sence and presence of rapamycin (Ins-Ra) 
and leptin ( h ) in the absence and presence 
of rapamycin (Lep-Ra) at the 30-min time 
point. n = 3 or 4 for each condition. Values 
are mean  8 SEM.  *  p  ! 0.05;  * * *  p  ! 0.001. 
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period and under the experimental conditions used here, 
had no effect on p-AMPK, p-ACC or total ACC (data not 
shown). In contrast, ghrelin (100 n M ) increased p-AMPK 
and p-ACC in GT1-7 cells ( fig. 4 a–c), although the mag-
nitude of this response was considerably less than with 
A-769662, with no effect on total AMPK ( fig. 4 a). Fur-
thermore, in direct AMPK activity assays, ghrelin sig-
nificantly increased   1-and   2-AMPK activity, also to
a much smaller extent than that obtained by 50   M 
A-769662 ( fig. 4 d), mirroring the immunoblot data. Com-
bined, these data are consistent with ghrelin acting to el-
evate AMPK activity in GT1-7 cells. 
 Recent studies have shown that ghrelin-induced acti-
vation of hypothalamic AMPK requires the calcium-de-
pendent activation of calcium/calmodulin-dependent 
protein kinase kinase 2 (CaMKK2), an upstream kinase 
for AMPK  [32] widely expressed in neurons  [33] . Ghrelin 
is thought to raise neuronal intracellular calcium by mul-
tiple mechanisms that include release from intracellular 
stores and influx of extracellular calcium through ion 
channels  [34] . Here, we demonstrate that ghrelin pro-
duced no significant change in the membrane potential 
(V m ) or firing rate of GT1-7 cells ( fig. 4 e). In the absence 
of ghrelin, V m was –48.6  8 1.5 mV and firing frequency 
was 0.47  8 0.11 Hz and 10 min after ghrelin (100 n M ) ap-
plication, the mean values were –50.3  8 1.2 mV (n = 9;
p  1 0.1) and 0.63  8 0.15 Hz (p  1 0.1), respectively. How-
ever, we detected a small, but significant effect of ghrelin 
on action potential amplitude and after-hyperpolariza-
tion amplitude in GT1-7 cells ( fig.  4 f). Thus, although 
there is no strong evidence to indicate that ghrelin acts to 
depolarize or excite GT1-7 cells, an increase in action po-
tential amplitude, coupled with a larger after-hyperpo-
larization, may indicate increased extracellular calcium 
entry. Complete inhibition of GT1-7 cell firing was 
achieved by treatment with the non-specific voltage-gat-
ed calcium channel blocker, cadmium (100   M ; data not 
shown), suggesting that GT1-7 action potentials are 
mainly voltage gated calcium channel dependent and that 
continual cell firing will maintain a constant small influx 
of calcium. Accordingly, using fura-2 fluorescence imag-
ing (see online suppl. fig. 1; for all online suppl. material, 
see www.karger.com/doi/10.1159/000334144), ghrelin in-
duced a small, but sustained, increase in intracellular cal-
cium ([Ca 2+ ] i ) in all GT1-7 neurons that responded to the 
addition of KCl (100 m M ) with a large transient increase 
in calcium ( fig. 4 g, h). Thus ghrelin raises [Ca 2+ ] i in GT1-
7 hypothalamic neurons, which may, at least in part, be 
a
b
c
d
 Fig. 3. A-769662 increases AMPK activity 
concomitant with reduced p-S6K.  a Rep-
resentative immunoblots for p-AMPK, to-
tal AMPK, p-S6K, total S6K, p-ACC and 
actin under control conditions (C) and in 
response to 50   M A-769662 at various 
time points.  b Mean normalized p-AMPK 
under non-stimulated conditions (Cont) 
and after stimulation with A-769662. 
Mean normalized p-ACC ( c ) and p-S6K 
( d ) under non-stimulated conditions 
(Cont) and after stimulation with 
A-769662. n = 5–6 for each condition. Val-
ues are means  8 SEM.  *  p  ! 0.05;  * * *  p  ! 
0.001. 
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a
b
c
d
e
f
g
h
i
j
 Fig. 4. Ghrelin increases AMPK activity in 
GT1-7 cells via increased CaMKK2.  a Rep-
resentative immunoblots for p-AMPK, to-
tal AMPK, p-ACC and actin under control 
conditions (C) and in response to 100 n M 
ghrelin. Mean normalized p-AMPK ( b ) 
and p-ACC ( c ) under non-stimulated con-
ditions (Cont) and after stimulation with 
ghrelin.  d Mean normalized AMPK-  1 
and -  2 subunit activity under non-stim-
ulated conditions (Cont) and  following 30 
min stimulation with 100 n M ghrelin or 50 
  M A-769662.  e Representative perforated 
patch clamp recording (I = 0 pA) from a 
GT1-7 cell under control conditions and 
following application of 100 n M ghrelin. 
 f Mean action potential and afterhyperpo-
larization amplitudes (n = 75 from 5 cells) 
under control (saline) conditions and fol-
lowing application of ghrelin (100 n M ). 
 g Representative traces from 3 separate 
GT1-7 cells showing the change in relative 
fluorescence (internal calcium concentra-
tion) under control conditions and follow-
ing application (sequential arrows) of 100 
n M ghrelin, 100 m M KCl and 5 m M EGTA, 
respectively.  h Mean normalized change 
in [Ca 2 + ] i under control conditions (Cont) 
and following application of ghrelin and 
KCl.  i Representative immunoblot for p-
AMPK under control (C) conditions, 10 
  M STO-609 (STO) and in response to 100 
n M ghrelin in the absence and presence of 
STO-609.  j Mean normalized p-AMPK 
under non-stimulated conditions (Cont), 
STO-609 alone and ghrelin in the absence 
and presence of STO-609. n = 3–7 for each 
condition. Values are means  8 SEM.  *  p  ! 
0.05;  * *  p  ! 0.01;  * * *  p  ! 0.001. 
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due to increased calcium entry. Consistent with raised 
[Ca 2+ ] i resulting in higher CaMKK2 activity, the ghrelin-
dependent induction of AMPK phosphorylation in GT1-
7 cells was blocked ( fig. 4 i, j) by a 30-min pre-incubation 
of cells with STO-609 (10   M ), a CaMKK2 inhibitor  [35] . 
Interestingly, basal p-AMPK was also diminished by 
STO-609, indicative of constitutive CaMKK2 activity in 
these cells. From these results, we predicted that ghrelin 
would decrease mTORC1 activity in GT1-7 cells. Indeed, 
although less effective than A-769662, ghrelin (100 n M ) 
induced a significant suppression of basal p-S6K in GT1-
7 cells following 30 and 60 min exposure ( fig. 5 a, b), with 
no effect on total S6K ( fig.  5 a). To confirm a role for 
AMPK in ghrelin-mediated mTORC1 modulation, GT1-
7 cells were treated for 30 min with ghrelin (100 n M ) in 
the presence (with a 30-min pre-incubation) or absence 
of the AMPK inhibitor, compound C (40   M ). Com-
pound C, in the absence of ghrelin, significantly inhib-
ited basal AMPK phosphorylation ( fig. 5 c, d), which co-
incided with increased S6K phosphorylation ( fig. 5 c, e). 
This suggests that basal AMPK activity is sufficient to 
elicit a tonic inhibitory effect on mTORC1 activity within 
GT1-7 cells. Furthermore, compound C blocked the abil-
ity of ghrelin to increase AMPK phosphorylation con-
comitant with reversal of ghrelin-mediated reduction of 
S6K phosphorylation ( fig. 5 c–e), indicating that ghrelin-
mediated modulation of mTORC1 activity is AMPK de-
pendent.
 Insulin, but Not Leptin, Prevents Ghrelin-Induced 
Inhibition of S6K Phosphorylation 
 We have demonstrated that leptin and insulin increase 
whereas ghrelin or direct activation of AMPK using 
A-769662 decrease mTORC1 activity, respectively, in 
GT1-7 cells. Consequently, these results suggest that, at 
least, part of the final hypothalamic output of anorexi-
genic and orexigenic hormone-mediated signalling may 
depend on integration of their actions on upstream (i.e. 
PI3K-PKB vs. AMPK) signalling pathways that converge 
on mTORC1-S6K. We therefore determined whether in-
a c
d
e
b
 Fig. 5. Ghrelin inhibition of mTORC1 in GT1-7 cells is AMPK 
dependent.  a Representative immunoblot of p-S6K, S6K and actin 
under control conditions (C) and in response to 100 n M ghrelin. 
 b Mean normalized p-S6K under non-stimulated conditions 
(Cont) and after stimulation with ghrelin.  c Representative im-
munoblots for p-AMPK and p-S6K under control conditions (C), 
with 40   M compound C (Cpd C) and in response to 100 n M ghre-
lin in the absence and presence of compound C. Mean normalized 
p-AMPK ( d ) and p-S6K ( e ) under non-stimulated conditions 
(Cont), with compound C and in response to ghrelin in the ab-
sence and presence of compound C. n = 3–7 for each condition. 
Values are means  8 SEM.  *  p  ! 0.05;  * *  p  ! 0.01;  * * *  p  ! 0.001. 
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creased AMPK activity could attenuate the anorexigenic 
hormone-driven increase in mTORC1 activity. Both the 
insulin- and leptin-mediated increases in S6K phosphory-
lation were significantly reduced in the presence (with 30 
min pre-incubation) of A-769662 ( fig. 6 a–c). This shows 
that direct stimulation of AMPK mimics the effect of the 
mTORC1 inhibitor, rapamycin, on anorexigenic hor-
mone-induced S6K phosphorylation. However, pre-incu-
bation of GT1-7 cells with 100 n M ghrelin had no signifi-
cant effect on the insulin-mediated increase in S6K phos-
phorylation ( fig.  6 d, e), perhaps reflecting the smaller 
effect of ghrelin on AMPK activity observed in compari-
son to A-769662 ( fig. 4 e). Hence, in GT1-7 cells, the in-
hibitory signal elicited by ghrelin, presumably through 
increased AMPK activity, is too weak to overcome the 
stimulatory insulin signal (via PI3K-PKB) to mTORC1, 
suggesting that the insulin signal dominates. In contrast, 
the stimulatory signal driven by leptin to mTORC1 is 
weaker than that of insulin, and pre-incubation with 
ghrelin (100 n M ) inhibits the leptin signal ( fig. 6 f).
 Increased mTORC1 Activity Inhibits
Ghrelin-Mediated AgRP Expression in the Mouse 
Arcuate Nucleus 
 To investigate whether modulation of AMPK and 
mTORC1 activity underlies the ability of ghrelin to 
 increase hypothalamic AgRP expression, we measured 
AgRP mRNA levels in mouse ARC tissue sections in re-
sponse to A-769662 or ghrelin under conditions similar 
to that used to demonstrate modified mTORC1 activity 
in the GT1-7 hypothalamic neurons. In order to demon-
strate significant upregulation of AgRP mRNA in re-
sponse to increased AMPK activity by A-769662 or ghre-
lin, basal AgRP was maintained at a low level (short 
 period of food withdrawal) prior to the preparation
of hypothalamic slices. A-769662-mediated increased 
AMPK phosphorylation in ARC tissue sections resulted 
in a large increase in AgRP mRNA expression ( fig. 7 a). 
Although much less effective than A-769662, ghrelin per 
se induced a more than two-fold increase in AgRP mRNA 
expression in mouse ARC, whereas under these experi-
a
b
c
d
e
f
 Fig. 6. Insulin, but not leptin, prevents 
ghrelin-mediated S6K phosphorylation. 
 a Representative immunoblot showing p-
S6K in response to 50   M A-769662 alone 
(A-7) and 50 n M insulin and 50 n M leptin 
in the absence and presence of 50   M 
A-769662. Mean normalized p-S6K un-
der non-stimulated conditions (Cont), 
A-769662 (A-7) and  insulin (Ins) ( b ) and 
leptin (lep) ( c ) in the absence and presence 
of A-769662.  d Representative immuno-
blot showing p-S6K under control condi-
tions (C), 100 n M ghrelin and in response 
to 50 n M insulin, in the absence and pres-
ence of 100 n M ghrelin, respectively. 
 e Mean normalized p-S6K in response to 
increasing concentrations of insulin in the 
absence and presence of ghrelin. Note that 
ghrelin, in the absence of insulin, reduced 
p-S6K levels. n = 3–6 for each condition. 
 f Mean normalized p-S6K in response to 
leptin alone or leptin following pre-treat-
ment of cells with ghrelin. Values are 
means  8 SEM.  *   p  ! 0.05;  * *   p  ! 0.01; 
 * * *  p  ! 0.001. 
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mental conditions neither insulin ( fig. 7 a, b) nor leptin 
(data not shown) alone had any effect on basal AgRP ex-
pression levels. The AMPK inhibitor compound C pre-
vented the increase in AgRP mRNA elicited by ghrelin
in hypothalamic tissue ( fig. 7 c). Thus, ghrelin mediates 
raised AgRP gene expression through increased hypo-
thalamic AMPK activity. Furthermore, the ghrelin-in-
duced increased AgRP expression was significantly at-
tenuated (with 30 min pre-incubation) by insulin ( fig. 7 b), 
although leptin had no effect on the ghrelin-mediated in-
crease in AgRP mRNA expression (data not shown). In a 
separate series of experiments in which mice were starved 
overnight, leptin was demonstrated to suppress AgRP 
mRNA levels as expected (data not shown). One explana-
tion for these outcomes is that AgRP mRNA transcrip-
tion is controlled, at least in part, by the integration of 
PI3K- and AMPK-dependent signalling through the 
mTORC1 pathway. Consequently, insulin may attenuate 
the ability of ghrelin to increase AgRP gene expression by 
sufficiently raised activity in the PI3K-PKB pathway re-
sulting in stimulation of mTORC1, although if AgRP ex-
pression is stimulated by much higher AMPK activity 
(driven by A-769662), insulin is unable to offset this in-
crease ( fig. 7 a).
 To confirm that the inhibition by insulin- on ghrelin-
mediated AgRP mRNA expression was dependent upon 
the PI3K-PKB-mTORC1 pathway, hypothalamic slices 
were pre-incubated for 20 min with 100 n M rapamycin, 
and then treated for 3 h with 100 n M ghrelin and 50 n M 
insulin, as described. In the presence of rapamycin, the 
inhibitory effect of insulin on ghrelin-dependent AgRP 
expression was significantly attenuated ( fig. 7 b), indicat-
ing that insulin inhibits the promotion of AgRP mRNA 
production by ghrelin in an mTORC1-dependent man-
ner. However, this lack of inhibition by rapamycin of 
ghrelin-mediated increased AgRP mRNA also indicates 
an additional action of ghrelin to increase AgRP mRNA 
levels that is AMPK dependent but mTORC1 indepen-
dent.
 Discussion 
 The raised levels of S6K phosphorylation by insulin 
and leptin were inhibited by the presence of rapamycin, 
strongly indicating that the kinase responsible for S6K 
phosphorylation in GT1-7 cells is mTORC1. The increase 
in mTORC1 activity driven by insulin and leptin in GT1-
7 cells was shown to require signalling through the PI3K-
PKB pathway. LY294002 and wortmannin, commonly 
used inhibitors of PI3K, inhibited leptin- and insulin-
induced S6K phosphorylation in GT1-7 cells. One major 
caveat regarding these compounds concerns their ability 
to also inhibit mTOR, the proposed downstream effector 
of the S6K pathway. However, whereas LY294002 has 
been reported to inhibit mTOR at concentrations similar 
a b c
 Fig. 7. Ghrelin increases arcuate AgRP mRNA levels by raising 
AMPK activity, an outcome prevented by insulin.  a Mean nor-
malized mouse arcuate AgRP mRNA following stimulation with 
50   M A-769662 (A-7), 50 n M insulin (Ins) and A-769662 (A-7) in 
the presence of insulin.   b Arcuate AgRP mRNA levels following 
stimulation with 100 n M ghrelin, 50 n M insulin, 100 n M rapamy-
cin (Ra), insulin in the presence of ghrelin and insulin in the 
presence of ghrelin and rapamycin.  c Arcuate AgRP mRNA fol-
lowing stimulation with 40   M compound C (Cpd C), 100 n M 
ghrelin (Ghr) and ghrelin in the presence of compound C. n = 
5–9 for each condition. Values are means  8 SEM.  *  p  ! 0.05; 
 * *  p  ! 0.01. 
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to those required for inhibition of PI3K, wortmannin has 
only been shown to inhibit mTOR at micromolar con-
centrations  [28] . Additionally, the PKB inhibitor, Akti, is 
a selective inhibitor of PKB, with very little direct effect 
on other kinase activity, including mTOR and S6K  [28, 
30] . Taken together these data indicate that leptin- and 
insulin-induced S6K phosphorylation is, at least partly, 
due to the activation of the PI3K-PKB pathway. Addi-
tionally, previous work has demonstrated that centrally 
or peripherally administered leptin and insulin increase 
hypothalamic S6K phosphorylation, in conjunction with 
their actions to reduce food intake and body weight  [8, 
9] . However, the mechanism by which these hormones 
increase hypothalamic mTORC1 activity has not been 
fully explored, with both induction of PI3K signalling 
and actions secondary to increased neuronal activity 
plausible. The data presented here support the notion 
that PI3K and PKB activity are required for insulin and 
leptin modulation of mTORC1 in hypothalamic neurons 
and indicate that both hormones utilize the canonical 
growth factor signalling pathway to increase mTORC1 
activity ( fig. 8 ). 
 The orexigenic action of ghrelin is likely associated 
with GHSR1a-dependent signalling in the hypothalamus 
 [16, 17, 34] and recent studies strongly suggest that in-
creased hypothalamic AMPK activity underpins ghrelin-
induced food intake  [33, 36] . Furthermore, activity of the 
upstream AMPK kinase, CaMKK2, is a central compo-
nent of ghrelin-mediated regulation of food intake and 
neuropeptide expression  [33] . Thus, CaMKK2 KO mice 
exhibited decreased hypothalamic AMPK activity, which 
was associated with reduced AgRP and NPY mRNA lev-
els and loss of response to ghrelin. Moreover, inhibition 
of hypothalamic CaMKK2 in control mice by intracere-
broventricular application of the CaMKK2 inhibitor, 
STO-609, inhibited food intake and induced weight loss. 
Therefore, it has been proposed that ghrelin mediates 
orexigenic actions via hypothalamic GHSR1a activation, 
increasing intracellular neuronal calcium, which drives 
CaMKK2 to raise AMPK activity  [37] . Consequently, we 
used GT1-7 cells to explore how this pathway is involved 
in hypothalamic ghrelin signalling. Previous work has 
indicated that ghrelin directly depolarizes and increases 
the firing rate of hypothalamic arcuate neurons, includ-
ing NPY-containing neurons  [5, 38] . Ghrelin also raises 
[Ca 2+ ] i levels in neurons and glia  [39–41] . However, the 
mechanisms by which ghrelin increase [Ca 2+ ] i appear 
complex, with reports of direct depolarization of neurons 
initiating channel-mediated extracellular calcium entry 
 [38–40] and release of calcium from thapsigargan-sensi-
tive intracellular stores  [41] . Here we demonstrated that 
although ghrelin does not depolarize or excite GT1-7 hy-
pothalamic neurons, it does induce a rise in [Ca 2+ ] i , which 
may in part be due to increased calcium entry during ac-
tion potential firing. As we were focused on determining 
the main constituents of the signalling pathway utilized 
by ghrelin to alter mTORC1 activity, we have not deter-
mined the exact sources of the raised [Ca 2+ ] i in this study. 
 Ghrelin also increased AMPK activity, as measured by 
increased p-AMPK and p-ACC and by direct kinase 
 activity assay in GT1-7 cells, with the ghrelin-mediated 
increase in p-AMPK prevented by the presence of the 
CaMKK2 inhibitor, STO-609. The increase in AMPK 
 activity also coincided, temporally, with a decrease in 
mTORC1 activity, with the latter outcome blocked by the 
presence of the AMPK inhibitor, compound C. At pres-
ent, STO-609 and compound C are the best available in-
hibitors of CaMKK2 and AMPK, respectively. However, 
a major caveat regarding both of these drugs is their 
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 Fig. 8. Model by which anorexigenic and orexigenic hormone sig-
nals may converge and regulate mTORC1 in hypothalamic neu-
rons. Signalling through molecules highlighted in orange/yellow 
leads to inhibition of food intake and increased energy expendi-
ture, whereas signalling through molecules highlighted in blue 
leads to increased food intake and reduced energy expenditure, 
with mTORC1, highlighted in green, acting as a key signalling 
node to various cell outputs involved in body weight and  metabolic 
control. GHSR1a = GH secretagogue receptor 1a;  CaMKK2 = 
calmodulin kinase kinase 2; AMPK = AMP-activated protein ki-
nase; JAK2 = janus kinase 2; IRS = insulin receptor substrate; 
PI3K = phosphoinositide 3-kinase; PDK1 = phospholipid-depen-
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 relative lack of selectivity, with inhibition of a wide range 
of kinases reported at concentrations that inhibit 
 CaMKK2 and AMPK  [28] . Nevertheless, these data are 
consistent with the model described above whereby ghre-
lin raises intracellular calcium levels, increasing activity 
of CaMKK2, thus raising the levels of p-AMPK and in-
creasing AMPK activity. Higher AMPK activity in these 
cells was therefore predicted to inhibit mTORC1 activi-
ty and antagonize the effects of the anorexigenic hor-
mones on mTORC1 signalling, as depicted in the model 
shown in  figure 8 . Indeed, increasing AMPK activity in 
GT1-7 cells using A-769662 resulted in suppression of 
basal mTORC1 activity and reversed insulin- and leptin-
stimulated mTORC1 activity. However, the ghrelin-in-
duced increased AMPK activity was not sufficiently ro-
bust to offset the insulin- or leptin-mediated increase in 
mTORC1 activity in these hypothalamic neurons. This 
outcome was consistent with our finding that insulin sig-
nalling through mTORC1 dominates over the ghrelin-
mediated signal for regulation of hypothalamic AgRP 
mRNA expression. We did not find that leptin or insulin 
attenuated hypothalamic AMPK activity in this study, in 
apparent contradiction to a previous report  [42] . How-
ever, it should be pointed out that the inhibition of AMPK 
by leptin requires time periods of about 3 h and in sepa-
rate studies (data not shown) we have observed decreased 
basomedial hypothalamic p-AMPK and p-ACC levels in 
mice 3 h following leptin injection. 
 It is clear from recent work that a modification of hy-
pothalamic AMPK activity impacts on the regulation of 
neuropeptide expression levels and energy homeostasis 
 [20, 21] . However, the downstream mediators of altered 
AMPK activity in relation to these outputs are presently 
unclear. Our results suggested to us that modulation of 
hypothalamic mTORC1 activity, through the activation 
of AMPK, might contribute to ghrelin-driven changes in 
neuropeptide expression. Indeed, previous work has 
demonstrated that changing hypothalamic AMPK activ-
ity modifies mTORC1 signal transduction and results in 
altered neuropeptide expression and food intake  [43, 44] . 
In support, a recent study has shown that decreasing hy-
pothalamic AMPK activity by intracerebroventricular 
administration of compound C or adenovirus-driven 
over-expression of dominant negative AMPK catalytic 
isoforms impairs the central orexigenic actions of ghrelin 
 [36] . Using freshly isolated wedges of ARC tissue, we 
demonstrate that pharmacological activation of AMPK 
by A-769662 increases AgRP mRNA levels as expected. 
Ghrelin also increases AgRP mRNA expression, an effect 
prevented by the AMPK inhibitor compound C. Further-
more, insulin, although having no effects per se (due to 
animals being close to a satiated state when tested), also 
inhibited the ability of ghrelin to increase AgRP mRNA 
expression in ARC tissue, an outcome prevented by the 
concomitant presence of rapamycin. Consequently, these 
data support the notion that mTORC1 acts as a signalling 
node in at least some hypothalamic neurons, allowing 
integration of signalling by anorexigenic and orexigenic 
hormones (see  fig. 8 ) to be coupled to neuropeptide ex-
pression. It is important to note that rapamycin per se did 
not significantly alter ghrelin-stimulated AgRP mRNA 
levels, indicating that ghrelin likely utilizes addition-
al, although AMPK-dependent, pathways to upregulate 
AgRP mRNA expression. For example, ghrelin has been 
reported to alter hypothalamic fatty acid metabolism 
pathways in an AMPK-dependent manner, through re-
duced fatty acid synthase levels and activity, reduced mal-
onyl-CoA content and higher carnitine palmitoyl trans-
ferase 1 (CPT1) activity  [36] . Furthermore, ghrelin in-
creases hypothalamic levels of mitochondrial uncoupling 
protein 2 (UCP2), in an AMPK- and CPT1-dependent 
manner, and UCP2 KO mice demonstrate insensitivity to 
ghrelin or pharmacological activation of hypothalamic 
AMPK in relation to altered food intake and NPY and 
AgRP mRNA expression levels  [45] . Thus, an additional 
signalling system, exhibiting dependence on AMPK ac-
tivity for ghrelin-mediated outputs in hypothalamic neu-
rons, such as changes in neuropeptide expression, may be 
through increased hypothalamic fatty acid   -oxidation 
and increased UCP2 activity  [31, 45] . 
 In summary, these data improve our current under-
standing of the molecular signals regulating neuropep-
tide expression and demonstrate that mTORC1 is an im-
portant component of a complex regulatory system in hy-
pothalamic neurons. mTORC1 acts to integrate signalling 
information from anorexigenic hormones such as insulin 
and leptin via PI3K-PKB, with that of the orexigenic hor-
mone ghrelin, via Ca 2+ -CaMKK2-AMPK in order to 
modulate AgRP neuropeptide expression. It is likely that 
these key hormone and nutrient sensor systems are fun-
damental components, not only of specific arcuate neu-
ron populations but also of other neurons and cell types, 
which act in concert to integrate and disseminate infor-
mation to alter various cellular output signals involved
in the regulation of energy homeostasis. For example, 
mTORC1 activation in the hypothalamus suppresses 
food intake, thereby creating a systemic negative feed-
back loop to maintain nutrient homeostasis, and
mTORC1 also increases nutrient mobilization into pe-
ripheral tissues through enhanced lipid storage in adi-
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pose tissue  [46] . It will therefore be interesting to deter-
mine whether a similar cross-talk mechanism involving 
hormone-dependent modulation of mTORC1 and AMPK 
occurs in peripheral tissues, particularly in relation to in-
sulin secretion from the pancreas and tissue insulin and 
leptin resistance. 
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